Foreword

References

• Kuriyama M. Prostate-specific antigen as a tumor marker in prostate cancer. Int J Urol 1994; 1: 99–113.
   PubMedGoogle Scholar
• Abrahamsson PA, Kuriyama M. Molecular forms of serum prostate-specific antigen: the clinical usefulness of percent free PSA to discriminate prostate cancer from BPH. Acta Urol Jpn 1998; 11: 925–30.
   Google Scholar
• The Japanese Urological Association and The Japanese Pathological Society General rules for clinical and pathological studies on prostate cancer. 2nd ed. Tokyo: Kanahara; 1992.
   Google Scholar
• Nishimura M, Funaoka H, Shirai A, Ishii Y, Sunahara N, Kuriyama M. Establishment of enzyme immunoassay (ETA) for prostate-specific antigen-ai-antichymotrypsin complex (PSA-ACT) in blood. Igaku-to-Yakugaku (Tokyo) 1999; 41: 1199–208.
   Google Scholar
• Kuriyama M, Ueno K, Shichiri Y, Oh-Ishi K, Yoshida 0, Akimoto S, et al. Clinical significance of PSA-a1-antichymotrypsin determination in prostate cancer. Urol Surg (Tokyo) 1995; 8: 951–8.
   Google Scholar
• Stamey TA. Second Stanford Conference on interna-tional standardization of prostate-specific antigen im-munoassay; September 1 and 2,1994. Urology 1995; 45: 173–84.
   PubMed Web of Science ®Google Scholar
• Kuriyama M, Ueno K, Uno H, Kawada Y, Akimoto S, Noda M, et al. Clinical evaluation of serum prostate-specific antigen-al -antichymotrypsin-complex value in diagnosis of prostate cancer. Int J Urol 1998; 5: 48–54.
   PubMedGoogle Scholar
• SPSS Advanced Statistics 7.5J. Chicago, IL: SPSS; 1998.
   Google Scholar
• Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979; 17: 159–63.
   PubMedGoogle Scholar
• Oesterling JE, Jacobson SJ, Chute CG, Guess HA, Girman CJ, Panser LA, et al. Serum prostate-specific antigen in a community-based population of healthy men; establishment of age-specific reference ranges. JAMA 1993; 270: 860–4.
   PubMed Web of Science ®Google Scholar
• Carter HB, Pearson JD, Metter EJ, Braut LJ, Cahn DW, Andres R, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 2215–20.
   PubMed Web of Science ®Google Scholar
• Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Riten-house HG, Ratliff TL, et al. Evaluation of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274: 1214–20.
   Google Scholar
• Egawa S, Soh S, Ohori M, Uchida T, Gohji K, Fujii A, et al. The ratio of free to total serum prostate specific antigen and its use in differential diagnosis of prostate carcinoma in Japan. Cancer 1997; 79: 90–8.
   PubMed Web of Science ®Google Scholar
• Kuriyama M, Kawada Y, Arai Y, Maeda H, Egawa S, Koshiba K, et al. Significance of free to total PSA ratio in men slightly elevated serum PSA levels: a cooperative study. Jpn J Clin Oncol 1998; 28: 661–5.
   PubMed Web of Science ®Google Scholar
• Imai K, Yamanaka H, Kubota Y, Mild M, Ito T, Akaza H, et al. Clinical utility of the free prostate specific antigen (PSA), ai -antichymotrypsin-complexed PSA, and free/total PSA ratio using the specific and sensitive enzyme-linked immunosorbent assay E-plate EIKEN PSA". Acta Urol Jpn 1998; 44: 755–63.
   PubMedGoogle Scholar
• Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. A prospective multicenter clinical trial. JAMA 1998; 279: 1542–7.
   PubMed Web of Science ®Google Scholar
• Benson MC, Whang IS, Pantuck AP, Ring K, Kaplam SA, Olsson CA, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992; 147: 817–21.
   PubMed Web of Science ®Google Scholar
• Uno H, Koide T, Kuriyama M, Ban Y, Deguchi T, Kawada Y. Prostate specific antigen density for dis-criminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen. Acta Urol Jpn 1999; 45: 47–61.
   Google Scholar
• Kuriyama M. The evaluation of PSA molecular forms, molecular ratio, and PSAD in the cases showing slightlyelevated serum PSA values for screening prostate cancer. Urol Surg (Tokyo) 1998; 11: 925–30.
   Google Scholar
• Papsidero LD, Wang MC, Valenzuela LA, Murphy GP, Chu TM. A prostate antigen in sera of prostate cancer patients. Cancer Res 1980; 40: 2428–32.
   Google Scholar
• Kuriyama M, Takeuchi T, Okano M, Fujimoto Y, Fujihiro S, Sakai S, et al. Enzyme immunoassay for detection of serum prostate antigen and prostatic acid phosphatase-binding globulins. Jpn J Urol 1983; 74: 1186–92.
   PubMedGoogle Scholar
• Chu TM, Kuriyama M, Johnson E, Papsidero LD, Killian CS, Murphy GP, et al. Circulating antibody to prostate antigen in patients with prostatic cancer. Transplant Proc 1984; 16: 481–5.
   PubMed Web of Science ®Google Scholar
• Stenman U-H, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan 0. A complex between prostate-specific antigen and a 1 -antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222–6.
   Google Scholar
• Lilja H, Christensson A, Dahlen U, Matikainen M-T, Nilsson 0, Pettersson K, et al. Prostate-specific antigen in serum occurs predominantly in complex with ai-antichymotrypsin. Clin Chem 1991; 37: 1618–25.
   Google Scholar
• Allard WJ, Thou Z, Yeung KK. Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. Clin Chem 1998; 44: 1216–23.
   Google Scholar
• Brawer MK, Meyer GE, Letran JL, Bankson DD, Morris DL, Yeung KK, et al. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 1998; 52: 372–8.
   PubMed Web of Science ®Google Scholar
• Chichibu K, Kuroe K, Hashimoto C, Goto S. Specific quantitation of y-seminoprotein- ai-antichymotrypsin complex in serum by monoclonal antibody based enzyme immunoassay. Jpn J Clin Pathol 1995; 43: 1153–8.
   PubMedGoogle Scholar
• Akimoto S, Ichikawa T, Ito H. Relationship of prostate-specific antigen levels to prostate volume and age in mass screening subjects. Urol Int 1998; 60: 216–9.
   Google Scholar
• Akimoto S, Masai M, Shimazaki J. Relationship between diurnal rhythm of serum testosterone and two prostatic markers (PSA and PAP) in untreated prostate cancer. Urology 1994; 43: 337–41.
   Google Scholar